- Report
- May 2026
- 161 Pages
Netherlands
From €4348EUR$4,850USD£3,752GBP
- Report
- May 2026
- 166 Pages
Spain
From €4348EUR$4,850USD£3,752GBP
- Report
- May 2026
- 169 Pages
United Kingdom
From €4348EUR$4,850USD£3,752GBP
- Report
- February 2026
- 150 Pages
Canada
From €4348EUR$4,850USD£3,752GBP
- Report
- February 2026
- 150 Pages
China
From €4348EUR$4,850USD£3,752GBP
- Report
- February 2026
- 150 Pages
Germany
From €4348EUR$4,850USD£3,752GBP
- Report
- February 2026
- 150 Pages
India
From €4348EUR$4,850USD£3,752GBP
- Report
- February 2026
- 150 Pages
Japan
From €4348EUR$4,850USD£3,752GBP
- Report
- November 2025
- 150 Pages
China
From €4348EUR$4,850USD£3,752GBP
- Report
- March 2025
- 150 Pages
Global
From €4348EUR$4,850USD£3,752GBP
- Report
- March 2025
- 150 Pages
Global
From €4348EUR$4,850USD£3,752GBP
- Report
- November 2023
- 164 Pages
Middle East, Africa
From €1345EUR$1,500USD£1,160GBP
- Report
- July 2023
- 147 Pages
Middle East, Africa
From €1345EUR$1,500USD£1,160GBP
- Report
- April 2023
- 326 Pages
Global
From €3227EUR$3,600USD£2,785GBP
- Report
- February 2022
- 185 Pages
Global
From €3227EUR$3,600USD£2,785GBP
- Report
- February 2025
- 130 Pages
Global
From €4348EUR$4,850USD£3,752GBP
- Report
- January 2025
- 120 Pages
Global
€4990EUR$5,963USD£4,457GBP
- Report
- October 2023
- 85 Pages
United States
From €4348EUR$4,850USD£3,752GBP
- Report
- July 2023
- 210 Pages
Global
From €4034EUR$4,500USD£3,481GBP
- Report
- November 2020
- 450 Pages
Global
From €4392EUR$4,900USD£3,791GBP

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs.
Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more